Ignite Creation Date:
2024-07-17 @ 11:33 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06464861
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-18
First Post:
2024-06-13
Brief Title:
Sequential Treatment of CD19 CARNK and 7x19 CAR-T in RR B Cell Lymphoma
Sponsor:
Second Affiliated Hospital School of Medicine Zhejiang University
Organization:
Second Affiliated Hospital School of Medicine Zhejiang University
Study Overview
Official Title:
Sequential Treatment With 7x19 CAR-T After Umbilical Cord Blood Derived CD19 CARNK in RelapsedRefractory B Cell Lymphoma
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
CD19-CARNKT
Brief Summary:
To study the safety and efficacy of cord blood-derived CD19 CAR-NK cells sequential with 7x19 CAR-T in relapse refractory B cell lymphoma
Detailed Description:
This is a single-center open single-arm clinical exploratory study to observe the safety and efficacy of cord blood derived CD19 CAR-NK cells sequential treatment with 7x19 CAR-T in relapse refractory B cell lymphoma This study consisted of two phases phase I CARNK cells preparation and infusion Day0 dose of 2 x 106 kg Phase II 7x19 CAR-T cells preparation and infusion Day7 dose 2106kg
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None